TNF and inflammatory bowel disease: Next, we probed the clinical relevance of CDK9i-repressed genes (defined as the top 250 genes repressed by NVP-2 with false discovery rate [FDR] <0.01) using gene expression data from colonic biopsies from an independent cohort of patients with IBD taken pre- and post-anti-TNF (infliximab) therapy (Mucosal Gene Expression Defects in IBD; ClinicalTrials.gov identifier: NCT00639821).34